PF 6480605

Drug Profile

PF 6480605

Alternative Names: PF-06480605

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease

Most Recent Events

  • 23 Sep 2016 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in Poland (IV) (EudraCT2016-001158-16)
  • 08 Sep 2016 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in USA (IV) (NCT02840721)
  • 18 Jul 2016 Pfizer plans a phase IIa trial for Ulcerative colitis (Treatment-experienced) in USA (IV) (NCT02840721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top